Lung-derived Mesenchymal Stromal Cell Post-transplantation Survival, Persistence, Paracrine Expression, and Repair of Elastase-injured Lung
Overview
Authors
Affiliations
While multipotent mesenchymal stromal cells have been recently isolated from adult lung (L-MSCs), there is very limited data on their biological properties and therapeutic potential in vivo. How L-MSCs compare with bone marrow-derived MSCs (BM-MSCs) is also unclear. In this study, we characterized L-MSC phenotype, clonogenicity, and differentiation potential, and compared L-MSCs to BM-MSCs in vivo survival, retention, paracrine gene expression, and repair or elastase injury after transplantation. L-MSCs were highly clonogenic, frequently expressed aldehyde dehydrogenase activity, and differentiated into osteocytes, chondrocytes, adipocytes, myofibroblasts, and smooth muscle cells. After intravenous injection (2 h), L-MSCs showed greater survival than BM-MSCs; similarly, L-MSCs were significantly more resistant than BM-MSCs to anchorage independent culture (4 h) in vitro. Long after transplantation (4 or 32 days), a significantly higher number of CD45(neg) L-MSCs were retained than BM-MSCs. By flow cytometry, L-MSCs expressed more intercellular adhesion molecule-1 (ICAM-1), platelet derived growth factor receptor alpha (PDGFRα), and integrin α2 than BM-MSCs; these proteins were found to modulate endothelial adherence, directional migration, and migration across Matrigel in L-MSCs. Further, L-MSCs with low ICAM-1 showed poorer lung retention and higher phagocytosis in vivo. Compared with BM-MSCs, L-MSCs expressed higher levels of several transcripts (e.g., Ccl2, Cxcl2, Cxcl10, IL-6, IL-11, Hgf, and Igf2) in vitro, although gene expression in vivo was increased by L-MSCs and BM-MSCs equivalently. Accordingly, both L-MSCs and BM-MSCs reduced elastase injury to the same extent. This study demonstrates that tissue-specific L-MSCs possess mechanisms that enhance their lung retention after intravenous transplantation, and produce substantial healing of elastase injury comparable to BM-MSCs.
Agyapong N, Dominguez-Ortega L, Macdonough B, Mulluso P, Patel S, Prajapati B bioRxiv. 2025; .
PMID: 39974876 PMC: 11839019. DOI: 10.1101/2025.02.08.637273.
Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement.
Huang S, Li Y, Zeng J, Chang N, Cheng Y, Zhen X Cell Transplant. 2023; 32:9636897231180128.
PMID: 37318186 PMC: 10278440. DOI: 10.1177/09636897231180128.
Definitive Endodermal Cells Supply an in vitro Source of Mesenchymal Stem/Stromal Cells.
Zhang Y, Yi Y, Xiao X, Hu L, Xu J, Zheng D Commun Biol. 2023; 6(1):476.
PMID: 37127734 PMC: 10151361. DOI: 10.1038/s42003-023-04810-5.
Doherty D, Roets L, Krasnodembskaya A Stem Cells. 2023; 41(5):431-443.
PMID: 36749355 PMC: 10183969. DOI: 10.1093/stmcls/sxad014.
Regenerative medicine in lung diseases: A systematic review.
Adamic N, Vengust M Front Vet Sci. 2023; 10:1115708.
PMID: 36733636 PMC: 9887049. DOI: 10.3389/fvets.2023.1115708.